Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Estimated Market Size of the Synagis Market In 2029?

In recent times, the synagis market has witnessed a XX (HCAGR) increase. The market that was valued at $XX million in 2024 is expected to expand to $XX million in 2025, marking a compound annual growth rate (CAGR) of XX%. The expansion over the historic period can be traced back to factors such as the rise in expenditure for chronic diseases, an upsurge in investment for research and development, an escalation in disease burden, a surge in hospital admissions, and the growing occurrence of chronic respiratory disorders.

Looking forward, the Synagis market is predicted to experience an XX (FCAGR) increase over the next several years, reaching a value of $XX million in 2029 with a compound annual growth rate (CAGR) of XX%. Various factors are anticipated to contribute to this growth in the forecast period and these include the amplification in R&D spending, an increased incident rate of RSV, rising demand for personalized care and telemedicine, an aging population, and a growing pediatric demographic in emerging markets. Key trends expected to shape the market in the forecast period consist of progress in RSV treatment, the expansion of biosimilars, clinical trial results, treatment advances, regulatory approvals, and the launching of combination vaccines.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20304&type=smp

What Are the Core Market Drivers Propelling Growth in the Synagis Industry?

Escalating occurrences of chronic respiratory illnesses are anticipated to boost the advancement of the synagis market in the future. Such long-term diseases strike the lungs and respiratory tract, leading to perpetual respiratory difficulties. The emergence of these conditions is influenced by many factors, like an aging demographic, lifestyle and smoking habits, hereditary and employment-related influences, and exposure to pollutants. Synagis (palivizumab) aids in warding off severe respiratory syncytial virus (RSV) infections in infants and kids who are at high risk, minimizing complications and flare-ups in individuals suffering from chronic respiratory diseases. For instance, a report by Public Health Scotland, an organization under the Scottish government, revealed in December 2023 that the presence of asthma diagnosed by doctors had risen from 16% in 2021 to 17% in 2022. Hence, the escalating incidences of chronic respiratory illnesses are fueling the expansion of the synagis market.

How Is the Synagis Market Segmented?

The synagis market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prophylaxis; Premature Infants With Bronchopulmonary Dysplasia (BPD); Congenital Heart Disease (CHD); Immunocompromised Infants And Children

2) By Formulation: 50 Milligrams (mg)/0.5 Milliliters (mL); 100 Milligrams (mg)/1 Milliliters (mL)

3) By Distribution Channel: Wholesale Distributors; Online Retailers

4) By End-User: Pediatric; Adults

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20304&type=smp

Which Regions Are Driving the Next Phase of the Synagis Market Growth?

North America was the largest region in the synagis market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the synagis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the Synagis Market?

The primary trend in the synagis market pertains to achieving official drug authorization, to establish a long-anticipated preventive treatment for respiratory syncytial virus. Drug endorsement involves the assessment and approval of a novel drug for commercial sale and application, by verification authorities, confirming its safety, effectiveness, and quality as per clinical trial data. For instance, AstraZeneca Pharma India Ltd., a biopharmaceutical firm based in India, received permission from the Central Drugs Standard Control Organisation (CDSCO) in September 2023 to distribute palivizumab, a prophylactic therapy for respiratory syncytial virus (RSV). This consent embraces the palivizumab 100 mg/ml injection, offered in 50 mg/0.5 ml and 100 mg/ml single-dose vial formats for intramuscular use. The treatment is suggested for newborns birthed at 35 weeks of gestation or less, patients needing treatment for bronchopulmonary dysplasia (BPD), and those suffering from hemodynamically significant congenital heart disease (CHD). This endorsement represents a significant milestone in enhancing RSV healthcare in India, being the country’s first available preventive therapy for RSV.

View the full report here:

https://www.thebusinessresearchcompany.com/report/synagis-global-market-report

How Is the Synagis Market Defined and What Are Its Core Parameters?

Synagis (palivizumab) is a medication used to prevent serious lower respiratory tract infections caused by the respiratory syncytial virus (RSV) in high-risk infants and children. It is a monoclonal antibody that works by binding to the RSV virus, preventing it from entering and infecting cells in the respiratory system.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20304

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model